CORONA vs NEPHROPLUS: Stock Comparison
CORONA REMEDIES is the larger company by market capitalisation. CORONA REMEDIES shows a lower P/E, a higher ROE and a higher dividend yield, while NEPHROCARE HEALTH SERV L shows lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CORONA leads 7; NEPHROPLUS leads 2 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | CORONA | NEPHROPLUS |
|---|---|---|
| Live Price | ₹2,010 | ₹611.55 |
| Day Change | 0.3% | -0.46% |
| Volume | 17,444 | 1.53 L |
| 52-Week High | ₹2,292.4 | ₹781.5 |
| 52-Week Low | ₹1,336.6 | ₹446 |
| Distance from 52W High | -12.32% | -21.75% |
Valuation
| Metric | CORONA | NEPHROPLUS |
|---|---|---|
| Market Cap | ₹12,313 Cr | ₹6,124 Cr |
| P/E Ratio | 61.87x | 79.5x |
| P/B Ratio | 16.49x | 5.47x |
| EPS | ₹9.83 | ₹3.19 |
| Book Value | ₹122.12 | ₹111.27 |
| Dividend Yield | 0.5% | 0% |
Growth
| Metric | CORONA | NEPHROPLUS |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | CORONA | NEPHROPLUS |
|---|---|---|
| ROE | 24.28% | -0.83% |
| ROCE | 20.94% | 5.17% |
| Net Margin | 13.19% | 7.69% |
| Operating Margin | 15.89% | 7.3% |
| Debt to Equity | 0.19x | 0.01x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | CORONA | NEPHROPLUS |
|---|---|---|
| Promoter Holding | 69% | 18.79%▼ 2.28 pp |
| FII Holding | 4.21%▲ 0.58 pp | 11.73%▲ 2.95 pp |
| DII Holding | 16.45%▲ 3.55 pp | 8.11%▼ 0.94 pp |
| Public Holding | 10.34%▼ 4.14 pp | 21.85%▲ 3.53 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CORONA REMEDIES and NEPHROCARE HEALTH SERV L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.